'
The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
Related Resources for this page:
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Future Directions
- Antibody-Drug conjugates
- Summary
- A brief history of ADCs
- Cancer effects
- Current research in ADCs
- Cytotoxic agent
- HER2
- HER ligands
- HER pathways slide decks and videos
- Glossary
- Receptor activation
- Dimerization
- HER Signaling
- Overview
- HER1/EGFR evaluation
- HER1/EGFR and prognosis
- HER1/EGFR as a therapeutic target
- Summary
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER2 dysregulation
- HER2:HER3 dimer
- HER2 and prognosis
- HER2 detection methods
- HER2 as a therapeutic target
- HER2 in breast cancer
- Summary
- HER2 in ovarian cancer
- HER3 dysregulation
- HER3
- HER3 evaluation
- HER3 as a therapeutic target
- HER3 in breast cancer
- HER3 in ovarian cancer
- HER4
- How are ADCs designed to work?
- Glossary
- Monoclonal antibody
- Multimedia Resources
- Receptor-Mediated Endocytosis
- Research ADCs
- Research MET
- Stable linker
- HER receptors
- Summary
- Targeting cancers with ADCs
- Therapeutic potential of HER pathways
- What are ADCs?
- What is Met?
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Summary
- Cancer effects
- Apoptosis
- Resisting apoptosis
- HER2
- Gastric Cancer
- HER ligands
- HER pathways slide decks and videos
- Glossary
- Receptor activation
- Dimerization
- Overview
- HER1/EGFR evaluation
- HER1/EGFR and prognosis
- HER1/EGFR as a therapeutic target
- Summary
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER2 dysregulation
- HER2:HER3 dimer
- HER2 and prognosis
- HER2 detection methods
- HER2 as a therapeutic target
- HER2 in breast cancer
- Summary
- HER2 in ovarian cancer
- HER3 dysregulation
- HER3
- HER3 evaluation
- HER3 as a therapeutic target
- HER3 in breast cancer
- HER3 in ovarian cancer
- HER4
- Glossary
- MAPK Signaling
- MEK Inhibitor (GDC-0973)
- Melanoma
- PI3K Inhibitor (GDC-0941)
- Research MET
- HER receptors
- Summary
- PI3K/Akt/mTOR Signaling
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- What is Met?
- Traditional Monoclonal Antibodies
- Summary
- Anti-EGFL7
- Cancer effects
- Glossary
- HER2
- Gastric Cancer
- HER ligands
- HER pathways slide decks and videos
- Glossary
- Receptor activation
- Dimerization
- HER Signaling
- Overview
- HER1/EGFR evaluation
- HER1/EGFR and prognosis
- HER1/EGFR as a therapeutic target
- Summary
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER2 dysregulation
- HER2:HER3 dimer
- HER2 and prognosis
- HER2 detection methods
- HER2 as a therapeutic target
- HER2 in breast cancer
- Summary
- HER2 in ovarian cancer
- HER3 dysregulation
- HER3
- HER3 evaluation
- HER3 as a therapeutic target
- HER3 in breast cancer
- HER3 in ovarian cancer
- HER4
- Melanoma
- Research MET
- HER receptors
- Summary
- Angiogenic Signaling
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- What is Met?
- Antibody-Drug conjugates
Dimerization Video
Potential Role of Dimerization
HER2+ Breast Cancer Slide Decks
Comprehensive overview of HER2 Dimerization Inhibitors (HDIs)
New: HER2 Dimerization iTunes app
Explore the potential of HER2 dimerization inhibition
View all downloadable resources
Share
What makes HER2 different?
HER2: a key receptor for dimerization
HER2 is a key receptor for dimerization. HER2 is the only receptor that exists in an "open" conformation, ready to dimerize with other HER family members. Because HER2 is continually ready to dimerize, the overexpression of HER2 promotes the excessive formation of HER2 dimers.3
Preclinical studies also show that HER2-containing dimers have increased signaling potency relative to those without HER2.2
The HER2 receptor
Please note: this video contains sound so please adjust volume